Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Midazolam × Genitourinary × Clear all

Phase

Phase 4 3 Phase 1 3 Phase NA 2 Phase 2 2 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3 Other solid neoplasm 1 Lymphoid 1 Genitourinary 1

Conditions

Prostate Cancer Metastatic 1

Interventions

pembrolizumab 69 Docetaxel 49 Nivolumab 45 Prednisone 34 enzalutamide 30 Gemcitabine 25 Cyclophosphamide 22 Paclitaxel 21 Cisplatin 21 Radiotherapy 19 Carboplatin 19 Bevacizumab 19 Abiraterone Acetate 18 Ipilimumab 16 atezolizumab 14 aldesleukin 13 Sunitinib 13 Magnetic Resonance Spectroscopy 13 fludarabine 12 Interleukin-2 12 avelumab 11 Pluvicto 11 Filgrastim 11 Everolimus 11 gallium 68 PSMA-11 10 fludarabine phosphate 10 enfortumab vedotin 10 durvalumab 10 cemiplimab 10 abiraterone 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03436485 2025-07-22

CYPIDES

Orion Corporation, Orion Pharma

Phase 1/2 Active not recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡